Advertisement

Calciumantagonisten

  • Thomas Eschenhagen

Zusammenfassung

Hauptgruppen der Calciumantagonisten sind die Dihydropyridine und die relativ stärker kardiodepressiv wirkenden Substanzen Verapamil und Diltiazem.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Arzneimittelkommission der deutschen Ärzteschaft (1997): Calciumantagonisten vom 1,4-Dihydropyridin- Typ. Dtsch Ärztebl 22: C-1122–C–1123Google Scholar
  2. Cohn JN, Ziesche SM, Loss LE, Anderson GF, V-HeFT Study Group (1995): Effect of felodipine on short-term exercise and neurohormone and long-term mortality in heart failure: Results of V-HeFT VIII. Circulation 92: 1–143Google Scholar
  3. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J; ASCOT Investigators (2005): Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 366: 895–906PubMedCrossRefGoogle Scholar
  4. Deutsche Gesellschaft für Kardiologie (2003): Leitlinien zur Behandlung der chronischen koronaren Herzkrankheit. Z Kardiol 92: 501–521Google Scholar
  5. Heidenreich PA, McDonald KM, Hastie T, Fadel B, Hagan V, Lee BK, Hlatky MA (1999): Meta-analysis of trials comparing b-blockers, calcium antagonists, and nitrates for stable angina. JAMA 281: 1927–1936PubMedCrossRefGoogle Scholar
  6. Makarounas-Kirchmann K, Glover-Koudounas S, Ferrari P (2009): Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers. Clin Ther 31: 1652–1663PubMedCrossRefGoogle Scholar
  7. Nationale Versorgungsleitlinie Chronische KHK. 2. Auflage, August 2013. Internet: http://www.versorgungsleitlinien.de/themen/khk/pdf/nvl_khk_kurz.pdf
  8. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, Berman L, Shi H, Buebendorf E, Topol EJ; CAMELOT Investigators (2004): Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 292: 2217–2225PubMedGoogle Scholar
  9. Packer M, O’Connor CM, Ghali JK, Pressler ML, Carson PE et al (1996): Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 335: 1107–1114PubMedCrossRefGoogle Scholar
  10. Rothwell PM, Howard SC, Dolan E, O´Brian E, Dobson JE, Dahlöf B, Poulter NR, Sever PS; ASCOT- BPLA and MRC Trial Investigators (2010): Effects of ß blockers and calcium channel blockers on within-individual variability and risk of stroke. Lancet Neurol 9: 469–480PubMedGoogle Scholar
  11. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002): The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981–2997Google Scholar
  12. The DEFIANT-II Research Group (1997): Doppler flow and echocardiography in functional cardiac insufficiency: assessment of nisoldipine therapy. Results of the DEFIANT-II Study. Eur Heart J 18: 31–40CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Thomas Eschenhagen
    • 1
  1. 1.Institut für Experimentelle und Klinische PharmakologieUniversitäts-Krankenhaus EppendorfHamburg

Personalised recommendations